LUXEMBOURG, May 28, 2020 /PRNewswire/ -- CordenPharma, a
full-service Contract Development & Manufacturing Organization
(CDMO) for the supply of APIs, Drug Products & Pharmaceutical
Packaging, announces the signing of an amendment to their existing
manufacturing agreement with Moderna, Inc. (Nasdaq: MRNA), a
clinical stage biotechnology company pioneering messenger RNA
(mRNA) therapeutics and vaccines to create a new generation of
transformative medicines for patients. The extension enables
CordenPharma to manufacture large-scale volumes of Moderna's lipid
excipients to be used in the manufacture of Moderna's vaccine
candidate (mRNA-1273) against the novel coronavirus
(SARS-CoV-2).
Under the terms of the agreement, the companies will further
extend their supply relationship by expanding the manufacturing
agreement originally signed in 2016 between Moderna and
CordenPharma Switzerland. The amended agreement now includes
CordenPharma Chenôve (FR) and CordenPharma Colorado (US) for the
manufacture of larger-scale volumes of lipids, while continuing to
draw upon CordenPharma Switzerland's long-standing reputation as a
leader in specialized lipid manufacturing. The expanded agreement
will begin immediately in order to rapidly meet Moderna's
increasing demand over the upcoming months, with an emphasis on
securing their future long-term supply.
Juan Andres, Moderna's Chief
Technical Operations and Quality Officer, comments, "We are pleased
to extend our agreement with CordenPharma. This expansion will
increase supply of lipid excipients used to manufacture our mRNA
products. We appreciate CordenPharma's global presence and CDMO
expertise as we scale manufacturing of mRNA-1273."
Dr. Michael Quirmbach,
CordenPharma's President & CEO comments, "We are thrilled to
extend our long-term agreement to help support Moderna by
leveraging our strong global network of GMP manufacturing
facilities across Europe and the
US to supply the immediate need of lipid excipients for their
coronavirus vaccine. We are hopeful Moderna's technology represents
a positive impact for people suffering from COVID-19 across the
globe, and we are honored to contribute to the industry as a
whole."
About CordenPharma
CordenPharma, the global pharmaceutical manufacturing platform
of ICIG, is a full-service Contract Development & Manufacturing
Organization for APIs, Drug Products, and Packaging. Through cGMP
facilities across Europe and the
US organized under four Technology Platforms – Peptides, Lipids
& Carbohydrates, Injectables, Highly Potent & Oncology, and
Small Molecules – CordenPharma experts translate complex projects
at any stage of development into high-value products.
Contact us or visit cordenpharma.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cordenpharma--moderna-extend-strategic-manufacturing-services-agreement-for-the-supply-of-lipid-excipients-to-be-used-in-modernas-vaccine-mrna-1273-against-the-novel-coronavirus-sars-cov-2-301066688.html
SOURCE CordenPharma